Clinical trials: sponsored by Hanmi Pharmaceutical Company Limited
Healthy Volunteers
A Study to Evaluate the Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy Volunteers
The purpose of this study is to evaluate the drug-drug interaction and safety of RLD2301 and RLD2007 after oral administration in healthy volunteers.
- Trial name
- NCT05862090
- Testing
- RLD2301, RLD2007
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2 alone in patients with essential hypertension inadequately controlled on RLD2001-2 monotherapy.
- Trial name
- NCT04830449
- Testing
- HCP1904-2, RLD2001-2
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT05199129
- Testing
- HCP1904-3, RLD2001-1
- Where
- South Korea
- Volunteers
- 166 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-1 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT04820907
- Testing
- HCP1904-1, RLD2001-1
- Where
- South Korea
- Volunteers
- 123 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203
The purpose of this study is to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability between RLD2202 and RLD2203 in healthy adult subjects
- Trial name
- NCT05481307
- Testing
- RLD2202, RLD2203
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
A randomized, open-label, single-dose parallel study to evaluate the pharmacokinetics, safety and tolerability of HCP1803 in healthy male volunteers.
- Trial name
- NCT05723549
- Testing
- HCP1803-3, RLD2002, HCP1904-1
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Locally Advanced Solid Tumor, Metastatic Solid Tumor
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT03284502
- Testing
- HM95573, cobimetinib, HM95573, cetuximab
- Where
- 9 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy Male Volunteers
Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501
A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic drug interactions and the Safety between HGP1607 and HGP1501 in Healthy Male Volunteers
- Trial name
- NCT03089112
- Testing
- HGP1607, HGP1501, HGP1607+HGP1501
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-erosive Gastroesphageal Reflux Disease
Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease
The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with Non-erosive gastroesphageal reflux disease.
- Trial name
- NCT04325620
- Testing
- HIP1601, HGP1805
- Where
- South Korea
- Volunteers
- 208 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy Volunteer
Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects
Primary objective - To evaluate food effect on the pharmacokinetics and the pharmacodynamics (PD) of a single oral dose of HIP1601 in healthy subjects under fed or fasting condition.
- Trial name
- NCT04204629
- Testing
- HIP1601 40mg
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Dyslipidemia
An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia
In this study, dyslipidemia patients visited the institutions during the study period and the effectiveness and safety of the treatment of Newvast® Tab(Atorvastatin) in real-practice.
- Trial name
- NCT05555238
- Testing
- single arm, single group(No interventional)
- Where
- South Korea
- Volunteers
- 1,716 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Aortic Stenosis, Aortic Regurgitation
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation between the intensive care group and the usual care group for patients with hypertension accompanied by aortic valve disease and…
- Conditions
- Aortic Stenosis, Aortic Regurgitation, Hypertension, LVM
- Trial name
- NCT03666351
- Testing
- Amlodipine 5mg, Losartan, Losartan and Amlodipine
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for…
- Trial name
- NCT05487560
- Testing
- Esomezol Cap
- Where
- South Korea
- Volunteers
- 4,133 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Study to Evaluate the Pharmacokinetics and Safety Between HCP1902 and Co-administration of RLD2007, RLD2008
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP1902 and co-administration of RLD2007/RLD2008 in healthy volunteers
- Trial name
- NCT04946903
- Testing
- RLD2007, RLD2008, HCP1902
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension,Essential
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
This study was to evaluate the therapeutic effect and safety of Amosartan Plus tablet administration in uncontrolled essential hypertension patients.
- Trial name
- NCT05462535
- Testing
- Amosartan Plus Tab.
- Where
- South Korea
- Volunteers
- 4,785 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Gastritis
Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis
The purpose of this study is to investigate the safety and clinical efficacy of HIP2101 in patients with acute or chronic gastritis.
- Trial name
- NCT05024721
- Testing
- HIP2101, RLD2101, HPP2101
- Where
- South Korea
- Volunteers
- 326 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects
An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HCP1801 in healthy subjects.
- Trial name
- NCT03826641
- Testing
- HCP1805, HCP1801
- Where
- South Korea
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response relationship of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT03897868)
- Testing
- HCP1803, Amlodipine, Losartan
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension
- Trial name
- HM_APOLLO (NCT04959305)
- Testing
- HCP1803-3, RLD2003, RLD2004
- Where
- South Korea
- Volunteers
- 245 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903
An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HCP1903 in healthy subjects.
- Trial name
- NCT04762407
- Testing
- HGP1910, HGP1909, HCP1903
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited